Stocks

JV for malaria drug may lift Ipca Laboratories

| Updated on December 20, 2019 Published on December 21, 2019

Ipca Laboratories on Friday said it has entered into an agreement with Medicines for Malaria Venture to jointly develop a novel antimalarial co-formulation Atoguanil, which contains the active pharmaceutical ingredients atovaquone and proguanil.

“Today, the manufacturing cost of atovaquone is believed to pose a barrier to widespread use of atovaquone-proguanil based products in malaria-endemic countries,” it added. Shareholders will closely monitor the developments.

Published on December 21, 2019
This article is closed for comments.
Please Email the Editor